93 related articles for article (PubMed ID: 11074537)
1. Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation.
Okugawa Y; Wada H; Noda T; Sakakura M; Nakasaki T; Watanabe R; Deguchi H; Gabazza EC; Mori Y; Nishikawa M; Deguchi K; Nobori T; Shiku H
Am J Hematol; 2000 Nov; 65(3):210-4. PubMed ID: 11074537
[TBL] [Abstract][Full Text] [Related]
2. Tissue factor pathway inhibitor and P-selectin as markers of sepsis-induced non-overt disseminated intravascular coagulopathy.
Mosad E; Elsayh KI; Eltayeb AA
Clin Appl Thromb Hemost; 2011 Feb; 17(1):80-7. PubMed ID: 19689998
[TBL] [Abstract][Full Text] [Related]
3. Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation.
Seo JW; Kim HK; Kim JE; Park S; Cho HI
Thromb Res; 2009 Feb; 123(4):565-72. PubMed ID: 18479738
[TBL] [Abstract][Full Text] [Related]
4. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
Wada T; Gando S; Mizugaki A; Yanagida Y; Jesmin S; Yokota H; Ieko M
Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
[TBL] [Abstract][Full Text] [Related]
5. Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor.
Puy C; Tucker EI; Matafonov A; Cheng Q; Zientek KD; Gailani D; Gruber A; McCarty OJ
Blood; 2015 Feb; 125(9):1488-96. PubMed ID: 25587039
[TBL] [Abstract][Full Text] [Related]
6. Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation.
Santamaria S; Reglińska-Matveyev N; Gierula M; Camire RM; Crawley JTB; Lane DA; Ahnström J
J Biol Chem; 2017 Jun; 292(22):9335-9344. PubMed ID: 28420729
[TBL] [Abstract][Full Text] [Related]
7. Evaluation the combined diagnostic value of TAT, PIC, tPAIC, and sTM in disseminated intravascular coagulation: A multi-center prospective observational study.
Mei H; Jiang Y; Luo L; Huang R; Su L; Hou M; Wang X; Deng J; Hu Y
Thromb Res; 2019 Jan; 173():20-26. PubMed ID: 30458338
[TBL] [Abstract][Full Text] [Related]
8. Caveolae optimize tissue factor-Factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor.
Maroney SA; Ellery PE; Wood JP; Ferrel JP; Bonesho CE; Mast AE
Biochem J; 2012 Apr; 443(1):259-66. PubMed ID: 22239091
[TBL] [Abstract][Full Text] [Related]
9. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.
Hackeng TM; Seré KM; Tans G; Rosing J
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3106-11. PubMed ID: 16488980
[TBL] [Abstract][Full Text] [Related]
10. A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis.
Hayakawa M; Sawamura A; Gando S; Jesmin S; Naito S; Ieko M
Thromb Res; 2012 Dec; 130(6):906-13. PubMed ID: 22353215
[TBL] [Abstract][Full Text] [Related]
11. Preliminary study of microparticle coagulation properties in septic patients with disseminated intravascular coagulation.
Meng S; Kang K; Fei D; Yang S; Gu Q; Pan S; Zhao M
J Int Med Res; 2021 May; 49(5):3000605211014094. PubMed ID: 34034547
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of haemostatic molecular markers for diagnosis of disseminated intravascular coagulation in patients with infections.
Asakura H; Wada H; Okamoto K; Iba T; Uchiyama T; Eguchi Y; Kawasugi K; Koga S; Mayumi T; Koike K; Gando S
Thromb Haemost; 2006 Feb; 95(2):282-7. PubMed ID: 16493490
[TBL] [Abstract][Full Text] [Related]
13. Anti-heparin/PF4 complexes by ELISA in patients with disseminated intravascular coagulation.
Matsuo T; Matsuo M; Sugimoto T; Wanaka K
Pathophysiol Haemost Thromb; 2007; 36(6):305-10. PubMed ID: 20224256
[TBL] [Abstract][Full Text] [Related]
14. Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor.
Tang H; Ivanciu L; Popescu N; Peer G; Hack E; Lupu C; Taylor FB; Lupu F
Am J Pathol; 2007 Sep; 171(3):1066-77. PubMed ID: 17640967
[TBL] [Abstract][Full Text] [Related]
15. Circulating hepatocyte growth factor as an independent prognostic factor of disseminated intravascular coagulation.
Chung S; Kim JE; Kim JY; Lee DS; Han KS; Kim HK
Thromb Res; 2010 Jun; 125(6):e285-93. PubMed ID: 20185166
[TBL] [Abstract][Full Text] [Related]
16. Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.
Horinaka S; Sugawara R; Yonezawa Y; Ishimitsu T
Br J Clin Pharmacol; 2018 Jan; 84(1):79-87. PubMed ID: 28888219
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
Chowdary P
Drugs; 2018 Jun; 78(9):881-890. PubMed ID: 29845491
[TBL] [Abstract][Full Text] [Related]
18. Factor VIIa-AT Complex Is an Independent Prognostic Marker of Disseminated Intravascular Coagulation.
Lee JH; Gu J; Kim HK
Ann Clin Lab Sci; 2021 Jul; 51(4):546-551. PubMed ID: 34452894
[TBL] [Abstract][Full Text] [Related]
19. Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia.
Chowdary P
Int J Hematol; 2020 Jan; 111(1):42-50. PubMed ID: 30302740
[TBL] [Abstract][Full Text] [Related]
20. Repeat dose exposure of PM
Liang S; Zhao T; Hu H; Shi Y; Xu Q; Miller MR; Duan J; Sun Z
Sci Total Environ; 2019 May; 663():245-253. PubMed ID: 30711591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
